Showing 6671-6680 of 9554 results for "".
- Merz Aesthetics Launches Radiesse (+) as First and Only Aesthetic Injectable to Improve Moderate to Severe Loss of Jawline Contourhttps://practicaldermatology.com/news/merz-aesthetics-launches-radiesse-as-first-and-only-aesthetic-injectable-to-improve-moderate-to-severe-loss-of-jawline-contour/2461062/Merz Aesthetics is launching Radiesse (+) Lidocaine for jawline contouring in adults over the age of 21. Radiesse (+) is the first and only U.S. Food and Drug Administration (FDA)-approved injectable treatment for jawline contour improvement. The FDA approved the supplemental
- New Guidelines from AAD Address Comorbidities of ADhttps://practicaldermatology.com/news/new-guidelines-from-aad-address-comorbidities-of-ad/2461060/New guidelines released this week by the American Academy of Dermatology (AAD)
- Morgan Dermatology to Expand with Financing from TD Bankhttps://practicaldermatology.com/news/morgan-dermatology-to-expand-with-financing-from-td-bank/2461058/Morgan Dermatology is expanding, thanks to a $1.38 million term loan and $5.26 million Commercial Real Estate Mortgage (CREM) from
- New Analysis Ranks Tremfya Highest Among PsA Treatments for Skin Clearancehttps://practicaldermatology.com/news/new-analysis-ranks-tremfya-highest-among-psa-treatments-for-skin-clearance/2461054/Tremfya® (guselkumab) ranks highest for skin clearance, based on Psoriasis (PsO) Area Severity Index (PASI) 90 response, among 23 psoriatic arthritis (PsA) treatment regimens, results of a newly reported Network Meta-Analysis (NMA) show. In terms of joint inflammation
- Allergan Aesthetics Announces Open Casting Call for BOTOX Cosmetichttps://practicaldermatology.com/news/allergan-aesthetics-announces-open-casting-call-for-botox-cosmetic/2461051/Allergan Aesthetics is hosting an open casting call seeking people who would like to share their BOTOX Cosmetic Story. Building on the success of the original
- Vial Connects with Advisory Board at 2022 Maui Dermatology Conferencehttps://practicaldermatology.com/news/vial-connects-with-advisory-board-at-2022-maui-dermatology-conference/2461050/Vial, in conjunction with the 2022 Maui Dermatology Conference, is hosting an Advisory Board co-hosted by Leon Kircik, MD, FAAD. Dr. Kircik and Vial, along with leading research sites, will discuss and collaborate on how Vial can continue to help grow dermatology research sites and tackle the big
- UCB Releases Positive Top-line Results for Bimekizumab in Second Phase 3 Psoriatic Arthritis Studyhttps://practicaldermatology.com/news/ucb-releases-positive-top-line-results-for-bimekizumab-in-second-phase-3-psoriatic-arthritis-study/2461047/UCB’s bimekizumab performed well in a Phase 3 study of active psoriatic arthritis patients who were inadequate responders or intolerant to anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. Significantly more patients treated with bimekizumab achieved 50 percent or great
- Survey Reveals Impact of AGA on Affected Men, Interest in New Therapieshttps://practicaldermatology.com/news/survey-reveals-impact-of-aga-on-affected-men-interest-in-new-therapies/2461046/Nearly two-thirds (64%) of men with androgentic alopecia (AGA) say the condition has a negative affect on their lives, yet more than half (56%) have never sought treatment for the condition, results of a survey show. Findings from the survey, conducted on behalf of
- Scientis: Mikki Bey Crawford Named US VP and General Manager, Aesthetic Dermatologyhttps://practicaldermatology.com/news/scientis-mikki-bey-crawford-named-us-vp-and-general-manager-aesthetic-dermatology/2461045/Mikki Bey Crawford is now US Vice President and General Manager, Aesthetic Dermatology for Scientis. In her new role, she will lead the sales and marketing teams to accelerate the growth of Cyspera® in the US. "We are so pleased t
- FDA Approves Pfizer's Cibinqo for Moderate-to-Severe AD in Adultshttps://practicaldermatology.com/news/fda-approves-pfizers-cibinqo-for-moderate-to-severe-ad-in-adults/2461037/Pfizer's Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, is now FDA approved for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including bi